Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Mesoblast Limited MESO
$3.63
-$0.03 (-0.82%)
На 18:01, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
543596040.00000000
-
week52high
4.35
-
week52low
2.14
-
Revenue
10211000
-
P/E TTM
-6
-
Beta
2.52824400
-
EPS
-0.69000000
-
Last Dividend
0.00000000
-
Next Earnings Date
30 мая 2023 г. в 04:00
Описание компании
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. The company has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Chardan Capital | Sell | Sell | 03 июн 2022 г. |
| Chardan Capital | Sell | Sell | 31 авг 2021 г. |
| Maxim Group | Buy | Hold | 07 апр 2021 г. |
| Jefferies | Hold | Buy | 19 янв 2021 г. |
| Maxim Group | Hold | Buy | 22 дек 2020 г. |
| Piper Sandler | Overweight | 06 сент 2022 г. | |
| Jefferies | Hold | Buy | 06 дек 2022 г. |
| Cantor Fitzgerald | Overweight | 01 февр 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
Mesoblast's (MESO) GVHD Drug BLA Gets FDA Priority Tag, Stock Up
Zacks Investment Research
09 мар 2023 г. в 08:24
Mesoblast (MESO) announces the FDA acceptance for review of the resubmitted biological license application for remestemcel-L for the treatment of children under 12 with steroid-refractory acute graft versus host disease. Stock gains on Wednesday, following the news.
Mesoblast Limited. (MESO) Q2 2023 Earnings Call Transcript
Seeking Alpha
02 мар 2023 г. в 04:21
Mesoblast Limited. (NASDAQ:MESO ) Q2 2023 Earnings Conference Call February 27, 2023 4:30 PM ET Company Participants Silviu Itescu – Chief Executive Officer Andrew Chaponnel – Chief Financial Officer Conference Call Participants Edward Tenthoff – Piper Sandler Swayampakula Ramakanth – HCW Silviu Itescu [Call Starts Abruptly] Thank you very much, operator.
Mesoblast Financial Results and Corporate Update Webcast
GlobeNewsWire
26 февр 2023 г. в 19:38
NEW YORK, Feb. 26, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operational highlights and financial results for the second quarter ended December 31, 2022.
Mesoblast Limited (MESO) Upgraded to Buy: Here's What You Should Know
Zacks Investment Research
15 дек 2022 г. в 13:32
Mesoblast Limited (MESO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Mesoblast Limited (MESO) Q1 2023 Earnings Call Transcript
Seeking Alpha
23 ноя 2022 г. в 08:50
Mesoblast Limited (NASDAQ:MESO ) Q1 2023 Results Conference Call November 22, 2022 4:30 PM ET Company Participants Dr. Silviu Itescu - CEO and MD Andrew Chaponnel - Interim CFO Dr. Eric Rose - Chief Medical Officer Conference Call Participants Carvey Leung - Cantor Fitzgerald Edward Tenthoff - Piper Sandler Dr. Silviu Itescu Good morning, good afternoon to the operational highlights and financial results for the quarter ended September 30, 2022, as well as our upcoming Annual General Meeting. Apologies for the slight delay due to technical difficulties; beyond our control.